Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | QoL in patients undergoing CAR T-cell therapy versus transplantation

Surbhi Sidana • 3 Jun 2019
ASCO 2019
Acute Lymphoblastic Leukemia B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Leukemia Lymphoma CAR-T

In this video, Surbhi Sidana, MD, of the Mayo Clinic, Rochester, MN, discusses the QoL in patients undergoing CAR T-cell therapy versus transplantation. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Surbhi Sidana

1:29
Managing toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
1:43
Ide-cel therapy for multiple myeloma with renal impairment
Surbhi Sidana • 8 Dec 2023
3:09
An overview of the toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
1:59
Real-world outcomes of ide-cel in heavily pre-treated R/R MM
Surbhi Sidana • 8 Dec 2023

Related Videos

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals